Drug Profile
GLS 409 - GLSynthesis
Alternative Names: GLS-409Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator GLSynthesis
- Class Nucleotides; Vasodilators
- Mechanism of Action Purinergic P2Y1 receptor antagonists; Purinoceptor P2Y12 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coronary thrombosis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Coronary-thrombosis in USA (IV, Infusion)
- 09 Dec 2017 Preclinical trials in Coronary thrombosis in USA (IV)